バイオ医薬品CDMOの世界市場の成長機会

当レポートでは、世界のバイオ医薬品CDMO市場について調査分析し、北米・欧州・アジア太平洋の3地域を対象とした2023年～2028年の6年間の市場収益の予測や、詳細なセグメント分析を提供しています。

目次

戦略的必須要件

• 成長がますます困難になっているのはなぜか
• The Strategic Imperative 8（TM）
• 世界のバイオ医薬品CDMO業界に対する上位3つの戦略的必須要件の影響
• 成長機会がGrowth Pipeline Engine（TM）を促進

成長機会の分析

• 分析の範囲
• 市場セグメンテーション：製品タイプ別
• 市場セグメンテーション：細胞発現システムタイプ別
• 市場セグメンテーション：サービスタイプ別
• バイオ医薬品CDMO市場における主な地域の競合
• 成長促進要因
• 成長抑制要因

成長環境－バイオ医薬品CDMO市場

• バイオ医薬品パイプラインの概要
• バイオ医薬品CDMOのビジネスモデル - バリューチェーンの拡大
• 精密医療を推進する次世代バイオ医薬品モダリティをサポートするための主なCDMO活動の概要
• CDMOに対するバイオシミラーの上市の影響
• バイオ医薬品CDMO業界の主な新動向
• 新規参入企業に道を開く新しいモダリティ
• 上市済みのバイオ医薬品の製品分布（2022年）
• バイオプロセシング技術の分布 - 哺乳動物ベース製造向けのシングルユースバイオリアクター（SUB）と固定床マルチユースバイオリアクター（MUB）
• バイオ製造能力の地域分布

成長機会の分析 - バイオ医薬品CDMO業界

• 世界のバイオ医薬品CDMO市場の主な成長指標
• 予測の枠組み - バイオ医薬品CDMOの市場規模
• 予測方法 - バイオ医薬品CDMO市場
• 予測の前提条件と考慮事項 - バイオ医薬品CDMO市場
• 収益予測 - 世界のバイオ医薬品CDMO市場
• 収益予測分析 - 世界のバイオ医薬品CDMO市場
• 収益予測：製品タイプ別
• 収益予測分析：製品タイプ別
• 収益予測：細胞発現システムタイプ別
• 哺乳類発現システムの収益予測分析
• 微生物発現システムの収益予測分析
• その他の発現システムの収益予測分析
• 収益分割：サービスタイプ別
• 競合環境
• 収益シェアの推定 - バイオ医薬品CDMO市場参入企業
• 収益シェア分析 - バイオ医薬品CDMO市場参入企業

成長機会

• 成長機会1：欧州におけるCGTの製造・販売能力の構築
• 成長機会2：アジアにおけるウイルスベクター製造能力の向上と拡大
• 成長機会3：生生物療法製品（マイクロバイオーム）の製造能力
• 成長機会4：バイオマニュファクチャリングにおけるAIとデジタルツインの採用
• 成長機会5：新しい治療法に向けた発見と前臨床サービス
• 成長機会6：CGT専用のPATサービス

次のステップ

Value Chain Expansion to Support Next generation Biologics Drives Future Growth Potential

This research service provides an overview of the global biologics contract development and manufacturing organization (bio-CDMO) market and a 6-year market revenue forecast (2023 to 2028). The geographic scope covers three key regions, namely North America (NA); Europe; and Asia-Pacific (APAC). The report offers a detailed segment analysis of the bio-CDMO market, including emerging business models such as reserved capacity and contract research development and manufacturing organization (CRDMO) services that are set to dominate the traditional fee-for-service manufacturing services space. The market segments cover drug type (drug substance and drug products) and cell expression type (microbial, mammalian, and other modalities). The other modalities segment includes cell-free expression systems, such as nucleic acid-based products and insect- and plant-based expression systems. For the purpose of this study, the bio-CDMO market forecast includes services encompassing drug development and manufacturing processes, such as product development (R&D) services, analytical support, and manufacturing and packaging services, into one integrated process (from drug development through manufacturing).

The industry shift toward biologics is boosting product pipelines and adoption, leading to more demand for biologics manufacturing capability and capacity expansion. Also, emerging biopharma companies hold two-thirds of the molecules in the R&D pipeline but have limited muscle to develop and commercialize these products. Bio-CDMOs can provide the agility and flexibility required for next-generation modalities such as CGT as they can use their modular facilities for multiple products and clients, which is a challenge for biopharma companies that build capabilities in-house. Big pharma is, therefore, increasingly choosing to outsource complex development and manufacturing processes and de-risking their supply chain instead of building more in-house manufacturing capacity. The transition of CDMOs to CRDMOs is leading them to offer end-to-end services. This positions competitors to partner with biopharmaceutical companies for their research, development, and manufacturing needs-from discovery to commercialization. While the COVID-19 pandemic has led to drug supply shortages, the pharmaceutical industry in general is moving toward right shoring, which involves keeping parts of the supply chain and processes in strategic locations to deliver the desired combination of cost and efficiency. CDMOs are playing a critical role in achieving supply chain resiliency.

Table of Contents

Strategic Imperatives

• Why is it Increasingly Difficult to Grow?
• The Strategic Imperative 8™
• The Impact of the Top Three Strategic Imperatives on the Global Biologics Contract Development and Manufacturing Organization (Bio-CDMO) Industry
• Growth Opportunities Fuel the Growth Pipeline Engine™

Growth Opportunity Analysis

• Scope of Analysis
• Market Segmentation by Product Type
• Market Segmentation by Cell Expression System Type
• Market Segmentation by Service Type
• Key Regional Competitors in the Bio-CDMO Market
• Growth Drivers
• Growth Restraints

Growth Environment-Bio-CDMO Market

• Biologics Pipeline Overview
• Bio-CDMO Business Model-Value Chain Expansion
• Overview of Key CDMO Activities to Support the Next-gen Biologics Modalities Driving Precision Medicine
• Impact of Biosimilar Launches on CDMOs
• Key Emerging Trends in the Bio-CDMO Industry
• New Modalities Paving the Way for New Entrants
• New Modalities Paving Way for New Entrants
• Product Distribution of Marketed Biologics in 2022
• Distribution of Bioprocessing Technique-Single-use Bioreactors (SUB) and Fixed Multiuse Bioreactors (MUB) for Mammalian-based Manufacturing
• Regional Distribution of Total Biomanufacturing Capacity

Growth Opportunity Analysis-Bio-CDMO Industry

• Key Growth Metrics for the Global Bio-CDMO Market
• Forecast Framework-Bio-CDMO Market Sizing
• Forecast Methodology-Bio-CDMO Market
• Forecast Assumptions and Considerations-Bio-CDMO Market
• Revenue Forecast-Global Bio-CDMO Market
• Revenue Forecast Analysis-Global Bio-CDMO Market
• Revenue Forecast by Product Type
• Revenue Forecast Analysis by Product Type
• Revenue Forecast by Cell Expression System Type
• Revenue Forecast Analysis for Mammalian Expression Systems
• Revenue Forecast Analysis for Microbial Expression Systems
• Revenue Forecast Analysis for Other Expression Systems
• Revenue Split by Service Type
• Competitive Environment
• Revenue Share Estimation-Top Bio-CDMO Market Participants
• Revenue Share Analysis-Top Bio-CDMO Market Participants

Growth Opportunity Universe

• Growth Opportunity 1: Building CGT Manufacturing and Distribution Capabilities in Europe
• Growth Opportunity 2: Improving and Expanding Viral Vector Manufacturing Capabilities in Asia
• Growth Opportunity 3: Live Biotherapeutic Products (Microbiome) Manufacturing Capabilities
• Growth Opportunity 4: Adoption of AI and Digital Twins in Biomanufacturing
• Growth Opportunity 5: Discovery and Preclinical Services for New Modalities
• Growth Opportunity 6: Purpose-built PAT Services for CGT

Next Steps

• Your Next Steps
• Why Frost, Why Now?
• List of Exhibits
• Legal Disclaimer